Abstract
Products of advanced protein glycosylation (advanced glycation end products, or AGEs) accumulate in tissues as a function of time and sugar concentration. AGEs induce permanent abnormalities in extracellular matrix component function, stimulate cytokine and reactive oxygen species production through AGE-specific receptors, and modify intracellular proteins. Pharmacologic inhibition of AGE formation in long-term diabetic animals prevents diabetic retinopathy, nephropathy, neuropathy, and arterial abnormalities in animal models. Clinical trials in humans are currently in progress.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 223-234 |
| Number of pages | 12 |
| Journal | Annual Review of Medicine |
| Volume | 46 |
| State | Published - 1995 |
Keywords
- Advanced glycation end products
- Aminoguanidine
- DNA
- Matrix
- Mitogens
- Receptors
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
